Defining severity in non-cystic fibrosis bronchiectasis

Expert Review of Respiratory Medicine

Volumn 8, Issue 2, 2014, Pages 249-262

  Poppelwell, Lucy ^a   Chalmers, James D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

bacteria; bronchiectasis; exacerbations; infection; mortality; neutrophil; prognosis; severity

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; MACROLIDE;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BRONCHIECTASIS; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DISEASE SEVERITY; EXERCISE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GENETICS; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION; MORTALITY; NON CYSTIC FIBROSIS BRONCHIECTASIS; PREDICTION; PRIMARY MEDICAL CARE; PROGNOSIS; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; REVIEW; RISK FACTOR; SCORING SYSTEM; SECONDARY HEALTH CARE;

BRONCHIECTASIS; DECISION SUPPORT TECHNIQUES; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84896758582     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.896204     Document Type: Review

References (87)

1. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2011;65(Suppl 1): i1-588
2. Cole PJ. Inflammation: a two-edged sword- the model of bronchiectasis. Eur J Respir Dis Suppl 1986;147:6-155
3. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013;55(1): 27-344
4. De Soyza A, Brown JS, Loebinger MR. Research priorities in bronchiectasis. Thorax 2013;68(7):695-66
5. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Executive summary. Revised 2011. Available from: www.goldcopd.org/uploads/users/files/ GOLD-Report-2011-Feb21.pdff
6. Calverley PM, Anderson JA, Bartolome C, et al. for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-899
7. British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Updated 2011. Available from: www. brit-thoracic.org.uk/Portals/0/Clinical% 20Information/Asthma/Guidelines/ sign101%20June%202011.pdf [Last accessed 27 December 2013]]
8. Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community acquired pneumonia. Thorax 2010;65(10):878-833
9. Chalmers JD, Singanayagam A, Akram AR, et al. Safety and efficacy of CURB65 guided antibiotic therapy in community-acquired pneumonia. J Antimicrob Chemother 2011; 66(2):416-233
10. Chalmers JD, Akram AR, Hill AT. Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis. Eur Respir J 2011;37(4):858-644
11. Du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184(4):459-666
12. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34(4):843-99
13. Bhalla M, Turcios N, Aponte V, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology 1991;179(3): 783-88
14. Reiff DB, Wells AU, Carr DH, et al. T findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995;165:261-77
15. Onen ZP, Gulbay BE, Sen E, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med 2007;101: 1390-77
16. Chalmers JD, Goeminne P, Aliberti S, et al. Derivation and validation of the bronchiectasis severity index: an international multicentre observational study. Am J Respir Crit Care Med 2013. [Epub ahead of print]]
17. Martinez-Garcia MA, de Gracia J, Vendrell-Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2013. [Epub ahead of print]]
18. Martinez-Garcia MA, De la Rosa Carrillo D, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187(8):823-311
19. Goeminne PC, Scheers H, Decraene A, et al. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012;13:211
20. Goeminne PC, Dupont LJ. Mortality in Non-Cystic fibrosis bronchiectasis: data from a large tertiary hospital in Belgium. Am J Respir Crit Care Med 2013;A35133
21. Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 2012;142:432-99
22. Ringshausen FC, de Roux A, Pletz MW, et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011L a population-based study of disease burden and trends. PLoS One 2013;8(8):e711099
23. Roberts ME, Lowndes L, Milne DG, Wong CA. Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis. Intern Med J 2012;42(6):e129-366
24. Joish VN, Spilbury-Cantalupo M, Operschall E, et al. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy 2013;11(3):299-3044
25. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132(5):1565-722
26. Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna JJ. Quality of life determinants in patients with clinically stable bronchiectasis. Chest 2005; 128(2):739-455
27. Aksamit TR, Carretta E, Daley CL, et al. The Bronchiectasis Research Registry: a Collaborative Research Cohort for Non-Cystic Fibrosis Bronchiectasis. Am J Respir Crit Care Med 2012;185(1):A86544
28. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-388
29. Wilson CB, Jones PW, O'Leary CJ, et al. Validation of the St. Georges Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997;156(2 pt 1): 536-411
30. Quittner AL, Cruz I, Marciel KK, et al. Development and cognitive testing of the quality of life questionnaire for bronchiectasis (QOL-B). Am J Respir Crit Care Med 2009;A43100
31. Schmit KM, Coeytaux RR, Goode AP, et al. Evaluating cough assessment tools: a systematic review. Chest 2013;144(6): 1819-266
32. Murray MP, Turnbull K, MacQuarrie S, et al. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(1): 125-311
33. Sheehan RE, Wells AU, Copley SJ, et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 2002;20:581-77
34. Swinson DR, Symmons D, Suresh U, et al. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol 1997;36: 689-911
35. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162(4 pt 1):1277-844
36. Chalmers JD, Smith MP, McHugh B, et al. Short and long term antibiotic therapy reduces airway and systemic inflammation in non-CF bronchiectasis. Am J Respir Crit Care Med 2012;186(7):657-655
37. Roberts H, Wells A, Milne D. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax 2000; 55(3):198-2044
38. Brody AS, Klein JS, Molina PL, et al. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr 2004;145:32-88
39. Robinson TE, Leung AN, Northway WH, et al. Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. J Pediatr 2001;138:553-99
40. Agarwal R, Khan A, Gupta D, et al. An Alternate Method of Classifying Allergic Bronchopulmonary Aspergillosis Based on High-Attenuation Mucus. PLoS ONE 2010;5:e153466
41. Devaraj A, Well AU, Meister MG, et al. Pulmonary hypertension in patients with bronchiectasis: prognostic significance of CT signs. AJR Am J Roentgenol 2011;196(6): 1300-44
42. Li Z, Kosorok MR, Farrell PM, et al. Longditudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293(5):581-88
43. Ratjen F, Munck A, Kho P, Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010;65:286-911
44. Doring G, Conway SP, Heijerman HGM, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-677
45. Davies G, Wells AU, Doffman S, et al. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006;28(5): 974-99
46. Evans SA, Turner SM, Bosch BJ, et al. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996;9(8):1601-44
47. Bahous J, Cartier A, Pineau L, et al. Pulmonary function tests and airway responsiveness to methacholine in chronic bronchiectasis of the adult. Bull Eur Physiopathol Respir 1984;20(3):75-800
48. Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009;33(2):312-188
49. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365(18):1663-722
50. Eisen DP. Mannose-binding lectin deficiency and respiratory tract infection. J Innate Immun 2010;2(2):114-222
51. Chalmers JD, Fleming GB, Hill AT, Kilpatrick DC. Impact of mannose binding lectin (MBL) insufficiency on the course of cystic fibrosis: a review and meta-analysis. Glycobiology 2011;21(3):271-822
52. Chalmers JD, McHugh BJ, Doherty CJ, et al. Mannose binding lectin deficiency and disease severity in non-CF bronchiectasis: a prospective study. Lancet Respiratory Medicine 2013;1(3):175-2744
53. Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178(2):139-488
54. Kilpatrick DC, Chalmers JD, MacDonald SL, et al. Stable bronchiectasis is associated with low serum L-ficolin concentrations. Clin Respir J 2009;3(1): 29-333
55. Kilpatrick DC, Chalmers JD. Human L-ficolin (ficolin-2) and its clinical significance. J Biomed Biotechnol 2012;2012:1387977
56. Chalmers JD, Kilpatrick DC, McHugh B, et al. Single nucleotide polymorphisms in the ficolin-2 gene predispose to Pseudomonas aeruginosa infection and disease severity in non-cystic fibrosis bronchiectasis. Thorax 2011;66(4):A1-22
57. Hsieh MH, Chou PC, Chou CL, et al. Matrix metalloproteinase-1 polymorphism (-1607G) and disease severity in non-cystic fibrosis bronchiectasis in Taiwan. PLoS ONE 2013;8(6):e662655
58. Bienvenu T, Sermet-Gaudelus I, Burgel PR, et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010;181:1078-844
59. Boyton RJ, Smith J, Ward R, et al. HLA-C and killer cell. immunoglobulin-like receptor genes in idiopathic bronchiectasis. Am J Respir Crit Care Med 2006;173: 327-333
60. Boyton RJ, Smith J, Jones M, et al. Human leukocyte antigen class II association in idiopathic bronchiectasis, a disease of chronic lung infection, implicates a role for adaptive immunity. Clin Exp Immunol 2008;152(1):95-1011
61. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008;31:396-4066
62. Watt AP, Brown V, Courtney J, et al. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax 2004;59(3):231-66
63. Angrill J, Agusti C, De Celis R, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001;164(9): 1628-322
64. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109(4):288-955
65. Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013;368(21): 1963-700
66. Sagel SD, Wagner BD, Anthony MM, et al. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012; 186(9):857-655
67. Murray MP, Pentland JL, Turnbull K, et al. Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(2):361-44
68. Goeminne PC, Vandooren J, Moelants EA, et al. The sputum colour chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis. Respirology 2013. [Epub ahead of print]]
69. Shoemark A, Debaraj A, Meister M, et al. Elevated peripheral airway nitric oxide in bronchiectasis reflects disease severity. Respir Med 2011;105(6):885-911
70. Zheng L, Tipoe G, Lam WK. Upregulation of circulation adhesion molecules in bronchiectasis. Eur Respir J 2000;16(4): 691-66
71. Wilson CB, Jones PW, O'Leary CJ, et al. Systemic markers of inflammation in stable bronchiectasis. Eur Respir J 1998;12(4): 820-44
72. Lee AL, Button BM, Denehy L, et al. Proximal and distal gastro-oseophageal reflux in COPD and bronchiectasis. Respirology 2013. [Epub ahead of print]]
73. Mandal P, Morice A, Chalmers JD, Hill AT. Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis. Respir Med 2013;107(7): 1008-133
74. Bronchiectasis severity index. Available from: www. bronchiectasisseverity.comm
75. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380(9842):660-77
76. Altenburg J, de Graff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309(12): 1251-99
77. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013;309(12): 1260-77
78. Albert RK, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365(8):689-988
79. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366(20): 1881-900
80. Schembri S, Williamson PA, Short PM, et al. Cardiovascular events following Clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013;346:f12355
81. Murray MP, Govan JRW, Docherty CJ, et al. A randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183(4):491-99
82. Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic bronchiectasis (ORBIT-2), a randomised double-blind placebo controlled trial. Thorax 2013;68(9):812-177
83. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41(5): 1107-155
84. McShane PJ, Naureckas ET, Tino G, Strek ME. Concise clinical review: non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013;188(6):647-566
85. Chalmers JD, McHugh BJ, Doherty CJ, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in non-CF bronchiectasis. Thorax 2012;68(1):39-477
86. Mandal P, Sidhu MK, Donaldsn LS, et al. Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. QJM 2013;106(1):27-333
87. Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013;187(10):118-26.